Rankings
▼
Calendar
REGN Q4 2025 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3.9B
+2.5% YoY
Gross Profit
$3.3B
84.9% margin
Operating Income
$880M
22.7% margin
Net Income
$845M
21.7% margin
EPS (Diluted)
$7.86
QoQ Revenue Growth
+3.5%
Cash Flow
Operating Cash Flow
$1.2B
Free Cash Flow
$922M
Stock-Based Comp.
$249M
Balance Sheet
Total Assets
$40.6B
Total Liabilities
$9.3B
Stockholders' Equity
$31.3B
Cash & Equivalents
$3.1B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.9B
$3.8B
+2.5%
Gross Profit
$3.3B
$3.2B
+2.4%
Operating Income
$880M
$990M
-11.1%
Net Income
$845M
$918M
-8.0%
Revenue Segments
Collaboration Revenue
$2.0B
51%
Product
$1.7B
43%
Product and Service, Other
$239M
6%
Geographic Segments
UNITED STATES
$3.3B
90%
Rest Of World
$361M
10%
← FY 2025
All Quarters